Company intelligence / Profile preview
CUTISS
Schlieren, Switzerlandcutiss.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
denovoSkin™ is currently in Phase III clinical trials in Europe. It has shown exceptional safety and efficacy results in Phase 1 trials for burns and reconstructions, and Phase 2 trials for burns and reconstructions. The product has received Orphan Drug Designation from Swissmedic, the European Medicines Agency (EMA), and the US FDA for the treatment of burns. The company has successfully treated its first patient in Boston, a pediatric patient.[2][5]
- Therapeutic areas
- OtherDermatology
- Modalities
- Personalized tissue therapyBioengineered skin grafts
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Tecan (announced April 14, 2025)
Beyond the preview
Go deeper on CUTISS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CUTISS.